Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 20 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $1,082,396, and 7 were calls, valued at $325,455.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $145.0 for Novo Nordisk over the recent three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 1369.56 with a total volume of 9,676.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $100.0 to $145.0 over the last 30 days.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO | PUT | SWEEP | NEUTRAL | 12/20/24 | $6.2 | $6.15 | $6.2 | $110.00 | $302.5K | 3.6K | 489 |
| NVO | PUT | SWEEP | NEUTRAL | 12/20/24 | $6.15 | $6.1 | $6.1 | $110.00 | $233.1K | 3.6K | 1.0K |
| NVO | CALL | SWEEP | BEARISH | 11/15/24 | $3.45 | $3.4 | $3.45 | $116.00 | $103.5K | 99 | 300 |
| NVO | PUT | SWEEP | BEARISH | 01/17/25 | $32.5 | $32.35 | $32.5 | $145.00 | $91.0K | 334 | 50 |
| NVO | PUT | SWEEP | BULLISH | 11/01/24 | $1.48 | $1.23 | $1.34 | $111.00 | $75.3K | 507 | 1.0K |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Novo Nordisk Standing Right Now?
- With a trading volume of 5,941,769, the price of NVO is down by -0.66%, reaching $111.62.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 8 days from now.
Professional Analyst Ratings for Novo Nordisk
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $158.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160. * Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Novo Nordisk, targeting a price of $156.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
